CRISPR Therapeutics AGCRSPNASDAQ
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank91
3Y CAGR+27.2%
5Y CAGR-3.4%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+27.2%/yr
vs -0.8%/yr prior
5Y CAGR
-3.4%/yr
Recent acceleration
Acceleration
+27.9pp
Accelerating
Percentile
P91
Near historical high
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $226.72M | +105.6% |
| 2024 | $110.25M | -15.4% |
| 2023 | $130.25M | +18.1% |
| 2022 | $110.25M | +9.0% |
| 2021 | $101.18M | -62.4% |
| 2020 | $269.41M | +50.2% |
| 2019 | $179.36M | +57.6% |
| 2018 | $113.77M | +63.0% |
| 2017 | $69.80M | +65.3% |
| 2016 | $42.24M | - |